Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Krystexxa Market Expansion From $ Billion In 2026 To $ Billion In 2030
The expansion observed during the historic period was driven by the shortcomings of standard gout treatments, a growing incidence of chronic gout, the demonstrated effectiveness of pegloticase in clinical settings, an increase in associated comorbid health issues, and the broader reach of specialized rheumatology clinics.
The expansion observed during the forecast period is driven by a rising number of patients with refractory gout, a higher rate of referrals to specialized clinics, broader availability of infusion services, favorable reimbursement policies for biologic treatments, and an ongoing lack of adequate options for managing severe gout. Key developments shaping this period involve the increasing adoption of biologic therapies for refractory gout, an emphasis on enzyme-based approaches to lower uric acid, specialized care for individuals with chronic gout, the growth of rheumatology services centered on infusion administration, and a growing utilization of these treatments in severe, treatment-resistant scenarios.
Download A Free Sample Report For Comprehensive Market Insights:
Krystexxa Market Expansion Drivers: What Is Shaping Future Growth?
The growing prevalence of gout disease is anticipated to boost the Krystexxa market in the coming years. Gout disease is a form of arthritis resulting from the accumulation of uric acid crystals within the joints, which causes inflammation, discomfort, and swelling. Various factors contribute to the rising incidence of this condition, including poor dietary choices, obesity, advancing age, certain medications, genetic predisposition, chronic kidney disease, a lack of physical activity, and accompanying health issues such as hypertension and diabetes. By lowering uric acid levels in the blood, Krystexxa (pegloticase) provides assistance to gout patients, particularly those with chronic gout that does not respond well to standard therapies, thus minimizing both the occurrence and intensity of gout attacks and alleviating the painful symptoms linked to this disorder. As an example, a June 2024 report from Rheumatology and Therapy, a US-based international peer-reviewed medical journal, indicated that the projected prevalence of comorbid gout and chronic kidney disease in the United States was set to climb from 7.9 million in 2023 to 8.6 million by 2027, further rising to 9.2 million in 2031, and eventually reaching 9.6 million in 2035—a 29% growth between 2023 and 2035. Consequently, the rising frequency of gout disease is fueling expansion in the Krystexxa market.
Krystexxa Market Segment Analysis Highlighting Growth Areas
The krystexxa market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions
2) By Indication: Treatment Of Chronic Gout, Management Of Hyperuricemia In Gout Patients, Treatment Of Refractory Gout
3) By Patient Demographics: Adult Patients, Elderly Patients, Patients With Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Specialty Clinics, Rheumatology Practices, Home Healthcare Providers
Krystexxa Market Strategic Trends: What Is Defining The Next Phase Of Growth?
A major trend shaping the Krystexxa market involves the progress of immunomodulatory approaches, exemplified by the rheumatology research dissemination initiative, which aims to boost the visibility of clinical evidence, facilitate well-informed therapeutic choices, and deepen stakeholder awareness of emerging developments in managing inflammatory and autoimmune conditions. This initiative represents a structured scientific communication strategy designed to present, distribute, and promote recent clinical findings, treatment data, and investigative insights within rheumatology. For example, in June 2024, Amgen Inc., a biotechnology firm headquartered in the United States, showcased innovative rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, unveiling fresh clinical data on Krystexxa (pegloticase). The presented research provided expanded evidence regarding treatment response patterns, patient-reported outcomes, and immunological dynamics associated with advanced therapeutic combinations. As a PEGylated uricase enzyme therapy, Krystexxa continues to offer distinct clinical advantages for adults with uncontrolled chronic gout by employing precision immune modulation to enhance efficacy and address anti-drug antibody formation. These new insights shared by Amgen reaffirm Krystexxa’s position as a leading biologic treatment for patients with severe gout who have not achieved adequate results with conventional therapies.
Krystexxa Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the krystexxa market are Amgen Inc.
Access The Complete Krystexxa Market Report:
Krystexxa Market Regional Analysis And Leading Geography
North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model